MARKET NEWS


Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials
Artelo Biosciences Announces Selection of Clinical Research Organization 
Disc Medicine Completes $50-Million Series A Financing, Enters Exclusive License Agreement With AbbVie
NervGen Pharma Expands Platform Into Alzheimer's Disease
Femtogenix Presents Novel Data on Antibody Drug Conjugates
Octapharma Adopts Genedata Bioprocess to Develop Next-Generation Bio-Manufacturing Processes

  FEATURED EDITORIAL

  COMPANY PROFILE

Frontida BioPharm, Inc. is a leading provider of  product development and manufacturing services for both small and large biotech, pharmaceutical, and consumer health companies. Combining the rich heritage of resources from URL/Mutual Pharmaceuticals in Philadelphia, PA, and Aurora, IL, with the development expertise from Frontage Laboratories and the region’s best pharmaceutical companies, Frontida is helping our partners reach the market faster, ensuring robust product performance and on-time supply of clinical and commercial products. Click here for more. 

  EXCLUSIVE ONLINE CONTENT

Aptar Acquires Noble International, a Leader in Drug Delivery Training Devices & Patient Onboarding

Aptar Acquires Noble International, a Leader in Drug Delivery Training Devices & Patient Onboarding

AptarGroup, Inc. recently announced it has acquired Noble International, a leader in drug delivery training devices and patient onboarding. This acquisition furthers Aptar’s strategy to broaden……

Flexion Announces Clearance of NDA for Gene Therapy Candidate

Flexion Announces Clearance of NDA for Gene Therapy Candidate

Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.

Cycle Pharmaceuticals & Catalent Partner to Develop Treatments for Rare Diseases

Cycle Pharmaceuticals & Catalent Partner to Develop Treatments for Rare Diseases

Cycle Pharmaceuticals Ltd. has recently signed an agreement with Catalent, Inc. to develop innovative formulations targeting rare disease patients.

 Ashland Launches New Excipient Solutions for Improved Drug Delivery 

 Ashland Launches New Excipient Solutions for Improved Drug Delivery 

Ashland recently announced the launch of three new pharmaceutical solutions, Plasdone S630 Ultra, Benecel XR and XRF, and Viatel bioresorbable polymers. Ashland is expanding its portfolio to meet formulators’ growing needs….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

Nov 13 – Prefilled Syringes
Nov 20 – Analytical Testing